Free Trial
NASDAQ:PALI

Palisade Bio (PALI) Stock Price, News & Analysis

Palisade Bio logo
$0.88 -0.12 (-12.16%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$0.89 +0.01 (+1.55%)
As of 08:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Palisade Bio Stock (NASDAQ:PALI)

Key Stats

Today's Range
$0.84
$1.90
50-Day Range
$0.61
$1.24
52-Week Range
$0.60
$4.32
Volume
94.69 million shs
Average Volume
1.15 million shs
Market Capitalization
$4.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Buy

Company Overview

Palisade Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

PALI MarketRank™: 

Palisade Bio scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Palisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Palisade Bio has only been the subject of 1 research reports in the past 90 days.

  • Read more about Palisade Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Palisade Bio are expected to grow in the coming year, from ($12.43) to ($2.99) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Palisade Bio is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Palisade Bio is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Palisade Bio has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Palisade Bio's valuation and earnings.
  • Percentage of Shares Shorted

    17.10% of the float of Palisade Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Palisade Bio has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Palisade Bio has recently decreased by 14.25%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Palisade Bio does not currently pay a dividend.

  • Dividend Growth

    Palisade Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.10% of the float of Palisade Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Palisade Bio has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Palisade Bio has recently decreased by 14.25%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Palisade Bio has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Palisade Bio this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for PALI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Palisade Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.28% of the stock of Palisade Bio is held by insiders.

  • Percentage Held by Institutions

    Only 11.79% of the stock of Palisade Bio is held by institutions.

  • Read more about Palisade Bio's insider trading history.
Receive PALI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter.

PALI Stock News Headlines

Critical AI announcement set to ignite AI 2.0
A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbling. But for smart traders, this isn’t chaos. It’s opportunity. One veteran trader is revealing how his simple system spots fast setups in moments like this—no guesswork, no complicated strategies, and no big account required.
See More Headlines

PALI Stock Analysis - Frequently Asked Questions

Palisade Bio's stock was trading at $1.65 at the start of the year. Since then, PALI stock has decreased by 46.8% and is now trading at $0.8784.

Palisade Bio, Inc. (NASDAQ:PALI) released its quarterly earnings results on Monday, May, 12th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.37.

Shares of Palisade Bio reverse split on the morning of Monday, April 8th 2024.The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Palisade Bio investors own include Onconova Therapeutics (ONTX), Sesen Bio (SESN), Iterum Therapeutics (ITRM), Oncobiologics (OTLK), Bionano Genomics (BNGO), PayPal (PYPL) and Tesla (TSLA).

Company Calendar

Last Earnings
5/12/2025
Today
8/07/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PALI
CIK
1357459
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

High Price Target
$16.00
Low Price Target
$8.00
Potential Upside/Downside
+1,266.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.44 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-178.96%
Return on Assets
-127.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.84
Quick Ratio
2.84

Sales & Book Value

Annual Sales
$250 thousand
Price / Sales
16.87
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.71 per share
Price / Book
0.32

Miscellaneous

Outstanding Shares
4,800,000
Free Float
4,639,000
Market Cap
$4.22 million
Optionable
Not Optionable
Beta
1.35
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:PALI) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners